Loading...

Hussein Yassine, MD

Title(s)Assistant Professor of Medicine
Phone+1 323 442 1909
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Beirut Arab University, Beirut, Lebanon 2002Dean's Distinguished Student Medicine Day Award
    Beirut Arab University, Beirut, Lebanon 2003Dean's Honor List on graduation
    Case Western Reserve University, Cleveland, OH 2007Resident Teacher of the Year Award
    2009Department of Veterans Affairs VISN 18 Outstanding Research Award
    2009Presidential Poster Award, Endocrine Society

    Collapse Overview 
    Collapse Overview
    Dr. Yassine is an Assistant Professor in the Department of Medicine, University of Southern California. The Yassine lab specializes in lipid metabolism, with an interest in Alzheimer's disease (AD).

    Carrying the APOE e4 allele is the strongest genetic risk factors for developing AD. Although only 20% of humans are APOE e4 carriers, these individuals account for up to 65% of all AD cases.

    Our research has been focused on the effect of APOE e4 on brain lipids in general and on the omega-3 fatty acid docosahexaenoic acid (DHA) in particular, and the mechanisms that regulate its brain delivery and metabolism.

    We demonstrated that lower levels of serum DHA associated with greater amyloid deposition in cognitively healthy older adults (JAMA Neurology, 2016), but not in patients with dementia (Alzheimer’s Research & Therapy, 2016). In patients with dementia, we identified an association between APOE e4 genotype and reduced levels of cerebrospinal fluid DHA after supplementation (Alzheimer’s Research & Therapy 2016).

    Using molecular studies, we identified that apoE apolipoproteins in cerebrospinal fluid have a decreased capacity to carry lipids by the ABCA-1 transporter, and that this lipid carrying capacity is lower in persons with mild cognitive impairment and Alzheimer’s compared to healthy controls (Journal of the American Heart Association, 2016).

    Using PET scans, we reported an increased incorporation coefficient for brain DHA in APOE e4 suggesting a deficit in brain DHA delivery in younger healthy APOE e4 carriers decades before the onset of AD. (Alzheimer’s Research & Therapy 2017).

    We hypothesize that apoE4 lipoproteins inefficiently transport lipids to brain areas involved in memory formation. Our long term goal is to demonstrate that AD pathology can be mitigated by enhancing apoE lipidation.

    More information can be found at www.yassinelab.com

    Collapse Research 
    Collapse Research Activities and Funding
    DHA brain delivery by APOE genotype
    NIH/NIA R21AG056518May 15, 2018 - Jan 31, 2020
    Role: Principal Investigator
    The delivery of essential fatty acids to the Brain in Alzheimer's disease
    NIH/NIA R01AG054434Sep 1, 2017 - Apr 30, 2022
    Role: Principal Investigator
    Biomarkers of ABCA1 mediated functions in Alzheimers disease
    NIH/NIA R01AG055770Jun 1, 2017 - May 31, 2022
    Role: Principal Investigator
    The Effect of Saturated Fat Ingestion on the HDL Proteome
    NIH/NHLBI K23HL107389May 15, 2012 - Apr 30, 2017
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Required Scholarly Project Mentor

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Kegulian NC, Ramms B, Horton S, Trenchevska O, Nedelkov D, Graham MJ, Lee RG, Esko JD, Yassine HN, Gordts PLSM. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. Arterioscler Thromb Vasc Biol. 2019 Aug 08; ATVBAHA119312723. PMID: 31390883.
      View in: PubMed
    2. Beale E, Lim E, Yassine H, Azen C, Christopher C. Development of a delayed-release nutrient for appetite control in adults with obesity and type 2 diabetes and initial clinical testing in a single dose randomized controlled trial. Nutr Diabetes. 2019 Jul 15; 9(1):20. PMID: 31308360.
      View in: PubMed
    3. Espeland MA, Hayden KM, Lockhart SN, Yassine HN, Hoscheidt S, Yasar S, Luchsinger JA, Neiberg RH, Brinton RD, Carmichael O. Sex-Related Differences in Brain Volumes and Cerebral Blood Flow Among Overweight and Obese Adults With Type 2 Diabetes: Exploratory Analyses from the Action for Health in Diabetes Brain Magnetic Resonance Imaging Study. J Gerontol A Biol Sci Med Sci. 2019 Apr 08. PMID: 30997482.
      View in: PubMed
    4. Lee S, Parekh T, King SM, Reed B, Chui HC, Krauss RM, Yassine HN. Low-Density Lipoprotein Particle Size Subfractions and Cerebral Amyloidosis. J Alzheimers Dis. 2019; 68(3):983-990. PMID: 30883362.
      View in: PubMed
    5. Yassine HN. Targeting prodromal Alzheimer's disease: too late for prevention? Lancet Neurol. 2017 12; 16(12):946-947. PMID: 29097165.
      View in: PubMed
    6. Jeffs JW, Ferdosi S, Yassine HN, Borges CR. Ex vivo instability of glycated albumin: A role for autoxidative glycation. Arch Biochem Biophys. 2017 09 01; 629:36-42. PMID: 28712850.
      View in: PubMed
    7. Yassine HN, Schneider LS. Lessons from the Multidomain Alzheimer Preventive Trial. Lancet Neurol. 2017 08; 16(8):585-586. PMID: 28721922.
      View in: PubMed
    8. Yassine HN, Croteau E, Rawat V, Hibbeln JR, Rapoport SI, Cunnane SC, Umhau JC. DHA brain uptake and APOE4 status: a PET study with [1-11C]-DHA. Alzheimers Res Ther. 2017 Mar 23; 9(1):23. PMID: 28335828.
      View in: PubMed
    9. Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, Harrington MG, Chui HC. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E e4 Carriers: A Review. JAMA Neurol. 2017 Mar 01; 74(3):339-347. PMID: 28114437.
      View in: PubMed
    10. Mendoza S, Trenchevska O, King SM, Nelson RW, Nedelkov D, Krauss RM, Yassine HN. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions. J Clin Lipidol. 2017 Jan - Feb; 11(1):224-233.e2. PMID: 28391889.
      View in: PubMed
    11. Yassine HN, Feng Q, Azizkhanian I, Rawat V, Castor K, Fonteh AN, Harrington MG, Zheng L, Reed BR, DeCarli C, Jagust WJ, Chui HC. Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis. JAMA Neurol. 2016 Oct 01; 73(10):1208-1216. PMID: 27532692.
      View in: PubMed
    12. Trenchevska O, Yassine HN, Borges CR, Nelson RW, Nedelkov D. Development of quantitative mass spectrometric immunoassay for serum amyloid A. Biomarkers. 2016 Dec; 21(8):743-751. PMID: 27308834.
      View in: PubMed
    13. Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016 06 30; 8:25. PMID: 27358067.
      View in: PubMed
    14. Yassine HN, Trenchevska O, Dong Z, Bashawri Y, Koska J, Reaven PD, Nelson RW, Nedelkov D. The association of plasma cystatin C proteoforms with diabetic chronic kidney disease. Proteome Sci. 2016; 14:7. PMID: 27019641.
      View in: PubMed
    15. Azizkhanian I, Trenchevska O, Bashawri Y, Hu J, Koska J, Reaven PD, Nelson RW, Nedelkov D, Yassine HN. Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. J Clin Lipidol. 2016 Jul-Aug; 10(4):808-815. PMID: 27578111.
      View in: PubMed
    16. Koska J, Yassine H, Trenchevska O, Sinari S, Schwenke DC, Yen FT, Billheimer D, Nelson RW, Nedelkov D, Reaven PD. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. J Lipid Res. 2016 05; 57(5):894-905. PMID: 26945091.
      View in: PubMed
    17. Yassine HN, Feng Q, Chiang J, Petrosspour LM, Fonteh AN, Chui HC, Harrington MG. ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease. J Am Heart Assoc. 2016 Feb 12; 5(2). PMID: 26873692.
      View in: PubMed
    18. Yassine HN, Trenchevska O, Ramrakhiani A, Parekh A, Koska J, Walker RW, Billheimer D, Reaven PD, Yen FT, Nelson RW, Goran MI, Nedelkov D. The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides. PLoS One. 2015; 10(12):e0144138. PMID: 26633899.
      View in: PubMed
    19. Kimzey MJ, Kinsky OR, Yassine HN, Tsaprailis G, Stump CS, Monks TJ, Lau SS. Site specific modification of the human plasma proteome by methylglyoxal. Toxicol Appl Pharmacol. 2015 Dec 01; 289(2):155-62. PMID: 26435215.
      View in: PubMed
    20. Yassine HN, Trenchevska O, He H, Borges CR, Nedelkov D, Mack W, Kono N, Koska J, Reaven PD, Nelson RW. Serum amyloid a truncations in type 2 diabetes mellitus. PLoS One. 2015; 10(1):e0115320. PMID: 25607823.
      View in: PubMed
    21. Yassine HN, Jackson AM, Reaven PD, Nedelkov D, Nelson RW, Lau SS, Borchers CH. The Application of Multiple Reaction Monitoring to Assess Apo A-I Methionine Oxidations in Diabetes and Cardiovascular Disease. Transl Proteom. 2014 Dec 01; 4-5:18-24. PMID: 25705587.
      View in: PubMed
    22. Borges CR, Rehder DS, Jensen S, Schaab MR, Sherma ND, Yassine H, Nikolova B, Breburda C. Elevated plasma albumin and apolipoprotein A-I oxidation under suboptimal specimen storage conditions. Mol Cell Proteomics. 2014 Jul; 13(7):1890-9. PMID: 24736286.
      View in: PubMed
    23. Yassine HN, Belopolskaya A, Schall C, Stump CS, Lau SS, Reaven PD. Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. Metabolism. 2014 May; 63(5):727-34. PMID: 24636347.
      View in: PubMed
    24. Yassine HN, Jackson AM, Borges CR, Billheimer D, Koh H, Smith D, Reaven P, Lau SS, Borchers CH. The application of multiple reaction monitoring and multi-analyte profiling to HDL proteins. Lipids Health Dis. 2014 Jan 08; 13:8. PMID: 24397693.
      View in: PubMed
    25. Yassine H, Borges CR, Schaab MR, Billheimer D, Stump C, Reaven P, Lau SS, Nelson R. Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin Appl. 2013 Aug; 7(7-8):528-40. PMID: 23696124.
      View in: PubMed
    26. Kastoon T, Stump CS, Thomson SP, Yassine H. Erlotinib-associated exacerbation of hypothyroidism with pericardial tamponade. Endocr Pract. 2012 Sep-Oct; 18(5):e111-3. PMID: 22440982.
      View in: PubMed
    27. Yassine H, Kimzey MJ, Galligan MA, Gandolfi AJ, Stump CS, Lau SS. Adjusting for Urinary Creatinine Overestimates Arsenic Concentrations in Diabetics. Cardiorenal Med. 2012 Feb; 2(1):26-32. PMID: 22493600.
      View in: PubMed
    28. Yassine HN, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF. Effect of glucose or fat challenge on aspirin resistance in diabetes. Int J Endocrinol. 2010; 2010:820876. PMID: 21318184.
      View in: PubMed
    29. Kimzey MJ, Yassine HN, Riepel BM, Tsaprailis G, Monks TJ, Lau SS. New site(s) of methylglyoxal-modified human serum albumin, identified by multiple reaction monitoring, alter warfarin binding and prostaglandin metabolism. Chem Biol Interact. 2011 Jun 30; 192(1-2):122-8. PMID: 20934417.
      View in: PubMed
    30. Yassine HN, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF. Clinical determinants of aspirin resistance in diabetes. Diabetes Res Clin Pract. 2010 Oct; 90(1):e19-21. PMID: 20719400.
      View in: PubMed
    31. Yassine HN, Marchetti CM, Krishnan RK, Vrobel TR, Gonzalez F, Kirwan JP. Effects of exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults--a randomized clinical trial. J Gerontol A Biol Sci Med Sci. 2009 Jan; 64(1):90-5. PMID: 19164269.
      View in: PubMed